Business Wire

Nacro Selects UniPrint Infinity™ to Deliver Secure and Efficient Citrix Printing across 110 UK Offices

Del

UniPrint.net (www.uniprint.net), the world leader in printing virtualisation solutions, have announced that Nacro, a criminal justice charity dedicated to reducing crime and re-offending in communities across England and Wales, have adopted UniPrint Infinity software to support their constant requirements of secure and trouble free printing across 110 offices. Nacro’s data centre is hosted offsite and runs on 40 Citrix XenApp 6.5 servers, delivering virtual desktops to 900 staff and volunteers with several specialist applications that require constant printing.

Printing problems occurred at the onset of a new Citrix deployment. Ben Bispham, ICT Infrastructure Support & Development Manager, Nacro reflects: “We struggled with printer mappings for 900 different users which caused significant problems with the combination of drivers and complexities of Windows printer deployment. This was made more difficult due to the number of users who frequently travel between offices. Users were frequently complaining of slow network performance, which was particularly evident during printing.”

With a diverse range of 250 printers across the network, it was time consuming to individually install printer drivers and continuously update them on the Citrix servers causing incompatibility and reliability issues. In addition, the Windows-based policy requiring printer mapping at each of the 110 offices further inundated the ICT Service Desk. Printing began to grind to a halt as users floundered over which printer to use. Users needed to ensure their print jobs would be printed to the correct location securely and on-demand. Even when the printer was correctly identified, printing was slow with limited bandwidth issues when large size print data was transmitted across asymmetric digital subscriber line (ADSL) connections. Frustration was setting in.

Upon testing the UniPrint Infinity printing software along with their vPad network print appliance, Nacro immediately experienced simplicity from working with just one UniPrint Universal Printer Driver (UPD) in their Citrix environment. This allowed them to replace all manufacturer specific printer drivers, significantly reducing printer management chores, eliminating incompatibilities and assuring ongoing stability. Remote printing speed also improved immediately as data stream compression kicked in. UniPrint’s Print Stream Compression feature compresses spooled print jobs by up to 95% promoting speedy data transmission to remote sites. Users’ wait time decreased from minutes to seconds.

Using the vPad secure pull printing feature, Nacro was able to assure client data confidentiality. Users simply tapped their RFID-enabled ID badge on the vPad and then released their document to the closest printer. Staff were able to print and release multiple documents together, saving time and increasing productivity. The pilot went so well that Nacro rolled out UniPrint Infinity and vPad secure pull printing across their offices and managed residencies. Installation was a straightforward plug and play, with no onsite configuration required. Half of the sites were self-installed and up and running within 10 minutes.

Nacro has also recorded cost and resource savings within the UniPrint installation. Using UniPrint’s Printer Profiles feature, Nacro has set all prints to black and white (mono) by default, so print cost is reduced to 0.5 pence from 4 pence (in colour) per page. In the back office, managing the virtual printing environment is now far less labour intense. IT only needs to manage and update a single UPD. With driver incompatibilities removed, the virtual Citrix server stability is also improved

Bispham concludes, “This has been a seamless install that alleviates multiple management headaches when printing across Citrix and critically, has placed the power and confidence of secure enabled print back into the hands of our staff.”

Most recently, Nacro have benefited from the ability to connect the vPads and printers at sites which are not on their domain and only have a standard internet connection. This has enabled secure cloud printing from within Citrix to these smaller remote sites across the internet.

For more information on UniPrint.net or download a free product trial, visit www.uniprint.net

About UniPrint:

UniPrint.net is the recognized leader in printing virtualization. The newest solution in UniPrint.net’s patented, award-winning product line, UniPrint Infinity is the industry’s first truly secure enterprise-wide solution for any computing environment. Enabling anywhere, anytime, and any device secure pull printing, UniPrint Infinity comes with a proven ROI through its statistics module, print document archiving functionality, secure mobile printing modules, and high availability setup with load balancing capability. UniPrint Infinity replaces all manufacturer printer drivers with a single PDF generator to promote faster, more efficient printing, helping organizations to improve both productivity and return on investments.

UniPrint Infinity™ is the trademark of UniPrint.net. All other trademarks and registered trademarks are properties of their respective owners.

Contact information

On Your Case Ltd
Sharon Munday, +44 (0) 7787 566382
sharon@onyourcase.co.uk

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l

Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19Pressemelding

Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom